J2O-MC-EKBC: KRAKEN: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Once-Daily LY3473329 in Adults with Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501466-21-00

Acronym

J2O-MC-EKBC

Enrollment

100

Registered

2023-02-09

Start date

2023-03-01

Completion date

2024-03-12

Last updated

2023-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipoprotein Disorder

Brief summary

Percent Change from Baseline in Lipoprotein (a) Lp(a) [Time Frame: Baseline to Week 12]

Interventions

DRUGPlacebo to match LY3473329

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percent Change from Baseline in Lipoprotein (a) Lp(a) [Time Frame: Baseline to Week 12]	—

Countries

Germany, Hungary, Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026